Analysis of the Clinicopathologic Characteristics of Men with Prostate Cancer Undergoing Radical Prostatectomy in the Prostate-Specific Antigen Range of Less than 4 ng/ml.
10.4111/kju.2009.50.4.320
- Author:
Taekmin KWON
1
;
In Gab JEONG
;
Jun Hyuk HONG
;
Hanjong AHN
;
Choung Soo KIM
Author Information
1. Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. cskim@amc.seoul.kr
- Publication Type:Original Article
- Keywords:
Prostate-specific antigen;
Prostatic neoplasms;
Prostatectomy
- MeSH:
Biopsy;
Cohort Studies;
Follow-Up Studies;
Humans;
Lymph Nodes;
Male;
Multivariate Analysis;
Neoplasm Grading;
Prostate;
Prostate-Specific Antigen;
Prostatectomy;
Prostatic Neoplasms;
Recurrence
- From:Korean Journal of Urology
2009;50(4):320-326
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: We analyzed the clinicopathologic characteristics of men undergoing radical prostatectomy in the prostate-specific antigen (PSA) range of less than 4 ng/ml and compared this with the results for men who had a PSA range of 4 to 9.9 ng/ml. MATERIALS AND METHODS: The study population consisted of 447 men treated for prostate cancer with radical prostatectomy between 1990 and 2006 at our institute who had a prebiopsy PSA of less than 10 ng/ml. The average follow-up period was 37 months. Clinicopathologic characteristics were compared between men with a PSA value of less than 4 ng/ml (low-PSA group) and men with a value in the range of 4 to 9.9 ng/ml (intermediate-PSA group). Survival analysis was performed by the Kaplan-Meier method and Cox proportional hazard regression analysis. RESULTS: Of these 447 patients, 60 (13.4%) and 387 (86.6%) had a low or an intermediate prebiopsy PSA level, respectively. The pathologic findings of the prostatectomy specimens showed no significant differences between the 2 groups, including Gleason score and pathologic stage. The 5-year biochemical recurrence-free survival in the low- and intermediate-PSA groups was 82.8% and 79.3%, respectively, and there was no significant difference between the 2 groups (p=0.946). Multivariate analysis showed that, in the entire cohort, pathologic Gleason score and lymph node involvement were independent predictors of biochemical recurrence. CONCLUSIONS: No statistically significant differences were found in clinicopathologic characteristics or clinical outcome between the low- and intermediate-PSA groups. These results suggest that a lower PSA cutoff should be considered as an indication for prostate biopsy in the Korean population.
